SABS
NASDAQ
US
SAB Biotherapeutics, Inc. - Common Stock
$3.88
▲ +$0.01
(+0.26%)
Vol 205K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$178.0M
P/E
9.5
ROE
33.4%
Margin
-1795.9%
D/E
2.01
Beta
0.62
52W
$1–$7
Wall Street Consensus
14 analysts · Apr 20265
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
92.9%
Buy Rating
Price Chart
Similar Stocks
FENC
Fennec Pharmaceuticals Inc
$262.9M
KRRO
Korro Bio Inc
$75.4M
NVCT
Nuvectis Pharma Inc
$193.4M
ANIK
Anika Therapeutics Inc
$138.6M
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
CRBP
Corbus Pharmaceuticals Holdings Inc
$142.9M
Earnings
Beat rate: 50.0%
Next Report
May 07, 2026
EPS Estimate: $-0.23
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.23 | — | — |
| Dec 2025 | $-0.20 | $-0.35 | $-0.15 |
| Sep 2025 | $-0.52 | $-0.15 | +$0.37 |
| Jun 2025 | $-0.81 | $-1.09 | $-0.28 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -153.9% | -153.9% | -153.9% | -153.9% | -153.9% | 33.4% |
| P/E (TTM) | — | — | — | — | — | 9.50 |
| Net Margin | — | -1795.8% | -1795.8% | -1795.8% | -1795.8% | -1795.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 27.87 | 27.87 | 27.87 | 27.87 | 27.87 | 2.01 |
| Current Ratio | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 10.50 |
Key Ratios
ROA (TTM)
25.3%
P/S (TTM)
134.60
P/B
1.3
EPS (TTM)
$-2.29
CF/Share
$-0.47
Rev Growth 3Y
-72.1%
52W High
$6.60
52W Low
$1.00
$1.00
52-Week Range
$6.60
How does SABS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SABS valuation vs Biotechnology peers
P/E ratio
9.5
▼
49%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
134.6
▲
947%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.4
▼
45%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SABS profitability vs Biotechnology peers
ROE
33.4%
▲
150%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-1795.9%
▼
526%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
25.3%
▲
154%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
SABS financial health vs Biotechnology peers
D/E ratio
2.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
10.5
▲
136%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.6
▼
36%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
SABS fundamentals radar
SABS
Peer median
Industry
SABS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
SABS vs peers: key metrics
Latest News
No related news yet